Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines

• Published in: Genes chromosomes & cancer 2021-06, Vol.60 (6), p.434-446
• Main Authors: Yang, Youfeng, Ricketts, Christopher J., Vocke, Cathy D., Killian, J. Keith, Padilla‐Nash, Hesed M., Lang, Martin, Wei, Darmood, Lee, Young H., Wangsa, Darawalee, Sourbier, Carole, Meltzer, Paul S., Ried, Thomas, Merino, Maria J., Metwalli, Adam R., Ball, Mark W., Srinivasan, Ramaprasad, Linehan, W. Marston
• Format: Article
• Language: English
• Subjects: Animals; c-Met protein; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; CDKN2A; Cell culture; cell line; Cell Line Authentication - methods; Cell Line, Tumor; Chromosomal Instability; Chromosome 7; Cyclin-Dependent Kinase Inhibitor p16 - genetics; Cyclin-Dependent Kinase Inhibitor p16 - metabolism; Gene deletion; hereditary type 1 papillary renal cell carcinoma; Humans; Kidney cancer; Kidney Neoplasms - genetics; Kidney Neoplasms - pathology; MET; Metastases; Mice; Mutation; Papillary renal cell carcinoma; Phosphorylation; pRCC; Proto-Oncogene Proteins c-met - genetics; Proto-Oncogene Proteins c-met - metabolism; Tumor cell lines; Xenograft Model Antitumor Assays - methods; Xenografts
• ISSN: 1045-2257; 1098-2264; 1098-2264
• DOI: 10.1002/gcc.22940

Renal cell carcinoma (RCC) is not a single disease but is made up of several different histologically defined subtypes that are associated with distinct genetic alterations which require subtype specific management and treatment. Papillary renal cell carcinoma (pRCC) is the second most common subtype after conventional/clear cell RCC (ccRCC), representing ~20% of cases, and is subcategorized into type 1 and type 2 pRCC. It is important for preclinical studies to have cell lines that accurately represent each specific RCC subtype. This study characterizes seven cell lines derived from both primary and metastatic sites of type 1 pRCC, including the first cell line derived from a hereditary papillary renal carcinoma (HPRC)‐associated tumor. Complete or partial gain of chromosome 7 was observed in all cell lines and other common gains of chromosomes 16, 17, or 20 were seen in several cell lines. Activating mutations of MET were present in three cell lines that all demonstrated increased MET phosphorylation in response to HGF and abrogation of MET phosphorylation in response to MET inhibitors. CDKN2A loss due to mutation or gene deletion, associated with poor outcomes in type 1 pRCC patients, was observed in all cell line models. Six cell lines formed tumor xenografts in athymic nude mice and thus provide in vivo models of type 1 pRCC. These type 1 pRCC cell lines provide a comprehensive representation of the genetic alterations associated with pRCC that will give insight into the biology of this disease and be ideal preclinical models for therapeutic studies.